No Picture

Astellas to Present New Data on Gilteritinib in Multiple Populations of FLT3 Mutation-Positive Acute Myeloid Leukemia (AML) Patients at the 2018 American Society of Hematology (ASH) Annual Meeting

– Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML –

TOKYO, Nov. 19, 2018 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today annou… […]

No Picture
Industry News

Immune therapy developed through Sanford Burnham Prebys and Lilly collaboration enters Phase 1 clinical trial

Sanford Burnham Prebys Medical Discovery Institute (SBP) today announced that the first healthy subject has been dosed in a Phase 1 clinical trial evaluating LY3361237, a biologic that inhibits inflammation by activating an immune checkpoint receptor. […]